Day: January 18, 2022

Innofactor Plc Inside Information, on January 18, 2022, at 14:40 Finnish time The Finnish Ministry of Social Affairs and Health selected Innofactor in a public procurement competition as the supplier of the case management, document management, transaction service and reference price information system of the Pharmaceuticals Pricing Board. In addition, Innofactor will provide the needed maintenance and further development services. The total value of the procurement (excluding VAT) stated by the Ministry of Social Affairs and Health in the procurement decision for the four-year contract period is approximately EUR 1,190,000. The Pharmaceuticals Pricing Board is subordinated to the Ministry of Social Affairs and Health, Deparment for Insurance and Social Security. The Pharmaceuticals Pricing Board confirms reimbursement and a reasonable...

TORONTO, Jan. 18, 2022 (GLOBE NEWSWIRE) — Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that the first patients have been treated in the Level 1 ‘CAPTAIN’ trial. CAPTAIN (A Comparison of TULSA Procedure vs. Radical Prostatectomy in Participants with Localized Prostate Cancer) is a prospective, multi-centre randomized controlled trial of 201 patients aimed at comparing the safety and efficacy of the TULSA procedure (performed with the TULSA-PRO® system) with radical prostatectomy (“RP”) in men with organ-confined, intermediate-risk, Gleason Score 7 (Grade Group 2 and 3) prostate cancer. In the CAPTAIN trial, 134 patients will be randomized to...

ROCKVILLE, Md., Jan. 18, 2022 (GLOBE NEWSWIRE) — OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease, announced today it is participating in Edison Group’s Open House Event, scheduled to take place virtually this month. The three-day event, in association with London Stock Exchange, global law firm Taylor Wessing and OpenExchange, will take place between 25th-27th January, focusing on 33 companies. Day one will feature businesses within pharmaceuticals & drug discovery, day two focuses on AI & technology in healthcare, while businesses adopting new approaches to hard-to-solve problems will round off the event. Content will be available to stream from January 25th on Edison’s website and OpenExchange.tv. Attendance...

Figure 1Picture of VAL-21-3-4: 22 metre spodumene pegmatite dyke.Figure 2Picture of VAL-21-3-4: 22 metre spodumene pegmatite dyke.Figure 3View of Vallée lithium property on the right side with Line 2, Line 3, and mapped spodumene pegmatites between Vallee and the North American Li Mine on the left.TORONTO, Jan. 18, 2022 (GLOBE NEWSWIRE) — Jourdan Resources Inc. (TSXV: JOR; OTCQB: JORFF) (“Jourdan” or the “Company”) is pleased to publish the final assay results of its September/October 2021 drilling campaign on its flagship Vallée project, which is located 35km north of Val-d’Or in Quebec, Canada. The results are from the last three drill holes and show multiple distinct zones of pegmatite intersections. Highlights of Line 3*:  Drill hole From(m) To (m) Length(m) Li2O(%)  VAL21-3-2 41.85 42.75 0.9 1.58  VAL21-3-2 42.75 43.7 0.95 1.31  VAL21-3-2 43.7 44.6 0.9 0.97  VAL21-3-3 31 31.9 0.9 0.92  VAL21-3-3 162.4 163.4 1 1.44  VAL21-3-4 71.2 72.05 0.85 1.06  VAL21-3-4 72.05 72.85 0.8 1.14  VAL21-3-4 100.7 101.8 1.1 1.63  VAL21-3-4 101.8 102.85 1.05 0.91  VAL21-3-4 102.85 103.95 1.1 1.32  VAL21-3-4 129.8 130.85 1.05 1.08  VAL21-3-4 177 191 14 0.67*drill...

– Positive feedback from FDA to initiate Phase 3 trial of atacicept in patients with LN – BRISBANE, Calif., Jan. 18, 2022 (GLOBE NEWSWIRE) — Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, announced plans to initiate a Phase 3 clinical trial of its lead product candidate atacicept in lupus nephritis (LN). This announcement comes after positive feedback from the U.S. Food and Drug Administration (FDA)’s review of the proposed Phase 3 trial. Lupus nephritis, a severe renal manifestation of systemic lupus erythematosus (SLE), causes kidney inflammation, which leads to blood and protein in the urine, high blood pressure, impaired kidney function, and eventually approximately 25...

Wesana’s novel and proprietary depression treatment protocol that includes a single high dose of psilocybin followed by a maintenance regimen of a microdose of psilocybin combined with cannabidiol, significantly reduced depressive behaviors in a validated animal model A single high dose of psilocybin alone demonstrated rapid, significant, and short acting improvement in depressive behaviors up to 14 days following administration Following the single high dose, the maintenance regimen of a microdose of psilocybin in combination with cannabidiol resulted in an additional and sustained 64% reduction in depressive behaviors relative to the psilocybin single high dose aloneCHICAGO and TORONTO, Jan. 18, 2022 (GLOBE NEWSWIRE) — Wesana Health Holdings Inc. (“Wesana” or the “Company”) (CSE: WESA; OTCQB: WSNAF), a data-driven life sciences...

Expansion into Europe is a key to global growth and revenue diversification strategy Flagship Endo-Kinetic therapeutic tech to assist STV members to meet their high standards of performance by incorporating recovery, health, and wellnessDENVER, Jan. 18, 2022 (GLOBE NEWSWIRE) — Omnia Wellness Inc. (the “Company”) (OTC US: OMWS), a health and wellness company providing advanced wellness and fitness therapeutic technologies has completed a pivotal step to enter the European athletic market by signing a Letter of Intent with the Swiss Gymnastics Federation (Schweizerischer Turnverband or STV). The Swiss Gymnastics Federation (STV), founded in 1985 and headquartered in Aarau, is the umbrella organization of cantonal/regional associations, gymnastics clubs, and is a member of the Swiss Olympic Association. STV is divided into 30 member...

Under Mydecine’s recently announced Special Access Support and Supply Program, the Company will supply cGMP Psilocybin and MDMA to The Newly. The companies will partner to co-develop protocols, therapy manuals, and training needed to treat patients who need specific care. VANCOUVER, British Columbia, Jan. 18, 2022 (GLOBE NEWSWIRE) — Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, today announced it has signed a Letter of Intent (LOI) with The Newly Institute Inc. (“The Newly”), a Calgary, Alberta based company opening private inter-disciplinary mental health clinics across Canada, to collaborate on expanding psychedelic-assisted psychotherapy to patients. The Newly...